Acyclovir injection and Mycophenolate Mofetil Oral Suspension
Determining the interaction of Acyclovir injection and Mycophenolate Mofetil Oral Suspension and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Coadministration with mycophenolic acid may increase the plasma concentrations of acyclovir. The mechanism of interaction has not been described. In 15 healthy subjects, coadministration of a single oral dose each of mycophenolate mofetil (1 gram) and acyclovir (800 mg) increased the peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and time to reach Cmax (Tmax) of acyclovir by 40%, 31% and 0.38 hour, respectively, compared to administration of acyclovir alone. In contrast, coadministration of mycophenolate mofetil with valacyclovir (2 gram) did not significantly alter acyclovir pharmacokinetics with the exception of a 0.5 hour decrease in Tmax. During coadministration with acyclovir or valacyclovir, pharmacokinetics of mycophenolic acid and its glucuronide metabolite, MPAG, were generally not significantly altered, although the AUC of MPAG decreased by 12% with valacyclovir. None of these changes are considered clinically relevant in healthy individuals. However, because both MPAG and acyclovir plasma concentrations are increased in the presence of renal impairment, the potential exists for the two drugs to compete for active tubular secretion, further increasing the concentrations of both drugs. Caution may be appropriate in patients with decreased renal function.
- "Product Information. Myfortic (mycophenolic acid)." Novartis Pharmaceuticals, East Hanover, NJ.
- "Product Information. CellCept (mycophenolate mofetil)." Roche Laboratories, Nutley, NJ.
- Gimenez F, Foeillet E, Bourdon O, et al. "Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects." Clin Pharmacokinet 43 (2004): 685-92
Generic Name: acyclovir
Brand name: Sitavig, Zovirax
Synonyms: Acyclovir, Acyclovir (Systemic)
Generic Name: mycophenolate mofetil
Brand name: Cellcept, Myfortic, MMF
Synonyms: Mycophenolate mofetil (oral/injection), Mycophenolate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Acyclovir injection-Mycophenolate mofetil oral/injection
- Acyclovir injection-Mycophenolate Mofetil Tablets
- Acyclovir injection-Mycophenolate sodium
- Acyclovir injection-Mycophenolate Suspension
- Acyclovir injection-Mycophenolate Tablets
- Acyclovir injection-Mycophenolate Tablets Delayed Release
- Mycophenolate Mofetil Oral Suspension-Acyclovir IV Infusion
- Mycophenolate Mofetil Oral Suspension-Acyclovir Ointment
- Mycophenolate Mofetil Oral Suspension-Acyclovir Oral Suspension
- Mycophenolate Mofetil Oral Suspension-Acyclovir Oral, Intravenous
- Mycophenolate Mofetil Oral Suspension-Acyclovir Sodium
- Mycophenolate Mofetil Oral Suspension-Acyclovir Suspension